Cresset Asset Management LLC Sells 41,175 Shares of GSK plc (NYSE:GSK)

Cresset Asset Management LLC decreased its position in shares of GSK plc (NYSE:GSK - Free Report) by 66.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,692 shares of the pharmaceutical company's stock after selling 41,175 shares during the quarter. Cresset Asset Management LLC's holdings in GSK were worth $707,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in GSK. Dorsey & Whitney Trust CO LLC boosted its position in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after purchasing an additional 278 shares in the last quarter. GC Wealth Management RIA LLC boosted its position in GSK by 2.6% during the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock valued at $474,000 after purchasing an additional 353 shares in the last quarter. Jacobi Capital Management LLC boosted its position in GSK by 3.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock valued at $352,000 after purchasing an additional 389 shares in the last quarter. Gladstone Institutional Advisory LLC boosted its position in GSK by 3.4% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock valued at $413,000 after purchasing an additional 407 shares in the last quarter. Finally, CENTRAL TRUST Co boosted its position in GSK by 5.6% during the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company's stock valued at $262,000 after purchasing an additional 414 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

GSK Trading Down 2.7%

Shares of NYSE:GSK opened at $36.36 on Wednesday. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93. The stock has a market cap of $75.02 billion, a price-to-earnings ratio of 22.87, a PEG ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The business has a 50-day moving average price of $37.56 and a 200-day moving average price of $35.97.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. During the same period last year, the business posted $0.43 earnings per share. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. Equities analysts predict that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.64%. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio (DPR) is currently 86.60%.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent research reports. Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. Morgan Stanley started coverage on GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. Finally, BNP Paribas started coverage on GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, GSK presently has a consensus rating of "Moderate Buy" and an average target price of $40.58.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.